Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib

BMJ Case Reports

Volumn , Issue , 2011, Pages

  Takenaka, Tomoyoshi ^a,b   Yamagata, Motoyuki ^b   Fukuda, Atsushi ^b   Sonoda, Takashi ^b  

^a NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^b Saiseikai Karatsu Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ERLOTINIB; FLUOROPYRIMIDINE; GEFITINIB; GEMCITABINE; STEROID;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CASE REPORT; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEADACHE; HUMAN; LUMBAR PUNCTURE; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME;

EID: 80053951859     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.08.2011.4586     Document Type: Article

References (8)

1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
2. Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005;103:2344-8. (Pubitemid 40686581)
3. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999;25:103-19.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. (Pubitemid 41058344)
5. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4:1415-9.
6. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fl uid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007;13:1511-5. (Pubitemid 46450442)
7. Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006;24:4517-20. (Pubitemid 46630993)
8. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281-9.